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estimated cost and effectiveness for four treatment strategies: 1) Standard dual
therapy pegylated interferon alfa and ribavirin (PR); 2) BOCPR triple therapy; 3)
TELPR triple therapy; and 4) no treatment. RESULTS: In our model, patients re-
ceived 1) PR for 48 weeks; 2) TEL for 12 weeks with PR for 34-36 weeks; or 3) BOC for
29 weeks with PR for 34-36 weeks. Estimated treatment cost associated with PR
alone, BOCPR, and TELPR are about $8,300, $31,000 and $45,000 per average
patient, respectively. Total system-wide costs to adopt BOCPR or TELPR would
be $673 million and $971 million, respectively. Assuming continuation of the cur-
rent 21% VHA treatment rates and optimal SVR results, the long term reduction in
liver related death from treatment PR, BocPR, and TelPR are 7.9%, 13.1%, and
14.5%, respectively.CONCLUSIONS:Our model indicates upfront investments with
BOCPR, and TELPR are high, with the benefits of extending quality of life and
lower costs due to liver-related morbidity. Though model projected potential cost
under these assumptions, a clinical trial of comparative effectiveness would be
needed to evaluate both costs and benefits of DAAs in veterans.
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OBJECTIVES: In Brazil, switching to a protease inhibitor (PI) based ARV regimen is
recommended as second line therapy for experienced patients failing non-nucle-
oside reverse transcriptase inhibitors. The BMS-045 study compared ATVRTV
and LPV/r regimens in ARV-experienced patients. Similar viral load (VL) suppres-
sion rates 400 copies were reported, but LPV/r provided greater suppression rate
50 copies. Total cholesterol (TC) levels improved to guideline levels in 23% of
ATVRTV patients and became elevated in 7% of LPV/r patients at 48 weeks. The
long term clinical and cost impact of this difference is not yet clear. The objective of
this study was to examine the long term HRQL and economic implications in Brazil
for LPV/r versus ATVRTV treatment of ARV-experienced patients. METHODS: A
previously published HIV Markov model was adapted. Baseline assumptions: TC
profile and CD4 cell distribution matching the BMS-045 population. HRQL and sur-
vival outcomes were measured in quality adjusted life years (QALYs). Costs in
Brazilian Reale were indexed to 2011. ARV costs and HIV treatment patterns were
based on Brazilian references. Lifetime costs/outcomes were discounted at 3% per
annum. A national health services perspective was adopted. RESULTS:VL suppres-
sion differences favored LPV/r, driving a net improvement in survival (0.31 QALYs,
106 days). Five and 10 year cost savings (BRL1,816, BRL1,496 per patient) were pro-
jected for LPV/r. Lifetime costs were slightly higher for LPV/r due to improved
survival. An incremental cost effectiveness ratio (ICER) of BRL2319 per QALY gained
was estimated for the LPV/r regimen, which is highly acceptable by Brazilian
threshold . CONCLUSIONS: Compared to ATVRTV, an LPV/r based regimen is cost
saving through the first 10 years of survival and is a cost effective use of public
resources for ARV-experienced Brazilian patients. LPV/r implementation is sup-
ported by its improved viral suppression, short/long term cost savings and favor-
able ICER.
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OBJECTIVES: Research data on antibiotic usage pattern and cost comparison are
scant in our country. Therefore we planned to identify oral antibiotic (OA) con-
sumption and cost comparison for 2010 in tertiary care hospital in Sri Lanka.
METHODS: Aggregate data for 2010 was collected from records of pharmacy and
unit price was obtained from medical supplies division. Initial and final stocks of
the OA, quantity received, quantities issued, quantity consumed and hospital data
from VEN analysis were obtained. We identified the top ten for total cost (TTTC)
and top ten for consumption (TTCS) OA. RESULTS: Ninethy-three percent of total
cost for TTTC was utilized for the top seven highly consumed OA with low unit
price. Seven percent of TTTC had been utilized for the drugs which were not in
TTCS. In contrast three drugs in TTCS had not been included in TTTC but in the list
of top 20. Low quota ( 2.5%) of the TTTC had been utilized for non essential drug in
VEN which was not even in TTCS of OA. CONCLUSIONS: Ninety-three percent of
the cost has been effectively utilized highly consumed low cost OA in this hospital
for 2010. Seven percent of money in TTTC was spent for expensive OA. We suggest
the authority to reconsider the change the drug ordering pattern with minimum
cost and to suitable alternative low cost generics instead of expensive product.
PIN28
CONSUMPTION PATTERN AND THE COST ANALYSIS OF PARENTERAL
ANTIBIOTICS IN A
Hettihewa LM, Subasinghe S, Nilakshi K, Cooray P
University of Ruhuna Faculty of Medicine, Galle, Sri Lanka
OBJECTIVES: We planned to identify the 2010 parenteral antibiotic (PA) consump-
tion pattern and its cost effectiveness in government teaching hospital using ag-
gregate data. METHODS: Aggregate data for 2010 was collected from pharmacy
records and unit prize was obtained from medical supplies division. Initial and final
stocks of the OA, quantity received, quantities issued and consumed per year were
obtained. Data for VEN analysis was collected. Data was analyzed to identify the
top ten for total cost (TTTC) and top ten for consumption (TTCS) PA according to the
total cost and the consumption separately. RESULTS: Ninety-three perecent of
TTTC was utilized for the top 7 highly consumed OA with low unit prize. Seven
percent of expenditure of TTTC was utilized for drugs which were not included in
TTCS. In contrast 3% of drugs (3 OA) in TTCS had not been included in TTTC. This
indicates that these three OAs are cost effectively used. 2.5% of the TTTC had been
used for a non essential drug in VEN which was not included even in TTCS of OA.
CONCLUSIONS: We conclude that 93% of the cost has been effectively utilized
highly consumed low cost OA in this hospital for 2010. Seven percent of the TTTC
had been spent for expensive oral antibiotics. We suggest the authority to recon-
sider the change the drug orders to maximize the cost effectiveness and prioritize
alternative low cost generics instead of expensive product orders.
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OBJECTIVES: One third of skin and soft tissue infections (SSTI) are caused by me-
thicilin-resistant staphylococcus aureus (MRSA). This study aims to compare SSTI-
MRSA treatment costs with linezolid versus branded and generic vancomycin un-
der the Brazilian private payer perspective. METHODS: A cost comparison study
was performed to compare linezolid versus generic and branded vancomycin. As
supported by clinical studies, overall treatment duration of 15 days with linezolid
and 14 days with vancomycin was considered, using PO linezolid after a minimum
4-days cycle of IV infusion while vancomycin (1g bid) was entirely IV. A decision-
tree model simulated SSTI-MRSA treatment assuming linezolid (600mg bid) IV can
be switched to PO after 4-days and patients can be discharged if PO is implemented
at physician discretion. Length of stay (LOS) and IV linezolid duration were ranged
in one-way sensitivity analysis. Only direct medical costs were included in the
analysis (hospital charges, medical visits, medical supplies and drug acquisition
costs) and unit costs were obtained from Brazilian official price lists (2010 USD
values). RESULTS: The linezolid scheme with 4-days IV (LOS4 days) and 11-days
PO resulted in overall costs per patient of 4089.58 USD, while branded and generic
vancomycin exhibited 6657.33 USD and 6970,23 USD, respectively. The incremental
cost of vancomycin-treated patients was driven by hospital daily charges, respon-
sible for over 55% of the overall vancomycin costs. One-way sensitivity analysis
revealed cost-savings for linezolid up to LOS 12 days, with overall costs per pa-
tient ranging from 4089.58 to 7428.84 USD if IV therapy was maintained throughout
the inpatient period (LOS15 days). CONCLUSIONS: Linezolid exhibited a cost-
saving profile over branded or generic vancomycin for the treatment of SSTI-MRSA
under the Brazilian public payer perspective. This economic benefit was a direct
result of potential early discharge of patients receiving PO linezolid.
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OBJECTIVES: Voriconazole (VOR) demonstrated better tolerability with a longer
treatment duration and less concomitant systemic antifungal drugs (con AF) com-
pared to itraconazole (ITR). This study assessed key cost components associated
with prophylaxis treatment of IFI after allogeneic HSCT across 4 countries (Canada,
France, Germany, and US). METHODS: A prospective open-label multicenter clini-
cal trial (IMPROVIT) for primary IFI prophylaxis after HSCT included patients12
years who were randomized to oral VOR or oral ITR from HSCT day for at least 100
and up to 180 days. Trial data on the key medical resource utilization (including
hospital days and con AF use) for the first 100 days were analyzed and valued in
2010 costs. RESULTS:A total of 224 patients were in VOR and 241 in ITR group, with
similar demographics (average age 43-year, 59% male, 92% Caucasian). VOR pa-
tients (vs. ITR) had longer study drug exposure (median: 96 vs. 68 days, p0.0001;
mean: 68 vs. 60 days, p0.0162) and were 2 times less likely (P0.0032) to use con
AF. The average per-patient hospital cost for voriconazole (vs. itraconazole) was
Can$27,674 (vs. Can$29,669), €13,277 (vs. €13,632), €15,185 (vs. €15,762), and $31,916
(vs. $33,521) in Canada, France, Germany, and the U.S., respectively. The average
per-patient cost of con AF for voriconazole (vs. itraconazole) was Can$1028 (vs.
Can$2290 p0.0061), €2208 (vs. €4678, p0.0095), €2422 (vs. €5033, p0.0177), and
$1,720 (vs. $3612, p0.0146) in the study countries respectively. Total costs varied
by country and were similar between treatment groups. The mean difference of 8
days in prophylaxis days between VOR and ITR was associated with 3.54%-4.55%
reduction (depending on the country) in inpatient cost (all p.0001) and 9.13%-
11.82% reduction in con AF cost (all p.01). CONCLUSIONS: Better tolerability of IFI
prophylaxis after HSCT was associated with cost offsets due to reduced hospital-
ization and concomitant antifungal use.
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